Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 12;12:5627–5638. doi: 10.2147/OTT.S198567

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Low dose of DAC does not impair CAR-T cell viability, proliferation, and cytolytic functions. RAJI cells were co-cultured with DAC as described in the text, and the drug was then washed out. The same numbers of viable CAR-T cells (E) or T cells (E) were plated with RAJI cells (T) in each experimental well at E:T ratio 1:1, and cultured overnight. Data were analyzed by FACS and depicted as mean ± SEM. MACSQuant was used for statistical analysis. (A) Specific killing of RAJI cells by CAR-T cells and T cells. (B and C) The production capacity of IFNγ or Granzyme B by CAR-T cells and T cells, respectively, after RAJI cells treated with or without DAC.

Abbreviations: CAR, chimeric antigen receptor; DAC, decitabine; FACS, fluorescence-activated cell sorting.